MX367674B - Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina. - Google Patents

Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.

Info

Publication number
MX367674B
MX367674B MX2015013965A MX2015013965A MX367674B MX 367674 B MX367674 B MX 367674B MX 2015013965 A MX2015013965 A MX 2015013965A MX 2015013965 A MX2015013965 A MX 2015013965A MX 367674 B MX367674 B MX 367674B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
olopatadine
mometasone
fixed dose
stable fixed
Prior art date
Application number
MX2015013965A
Other languages
English (en)
Other versions
MX2015013965A (es
Inventor
Dhuppad Ulhas
Katkurwar Ashok
Gupta Yashwant
Ankam Rajesh
Dhatrak Chandrakant
Original Assignee
Glenmark Specialty Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51688369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367674(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Specialty Sa filed Critical Glenmark Specialty Sa
Publication of MX2015013965A publication Critical patent/MX2015013965A/es
Publication of MX367674B publication Critical patent/MX367674B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica acuosa de dosis fija estable (p. ej., contenida en un recipiente) para administración nasal a un ser humano que comprende mometasona o su sal y olopatadina o su sal. La composición además puede incluir un hidrocoloide. La invención también se refiere a un proceso para preparar la composición farmacéutica y el uso de la composición farmacéutica en el tratamiento de la rinitis en un sujeto.
MX2015013965A 2013-09-13 2014-09-04 Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina. MX367674B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2975MU2013 2013-09-13
PCT/IB2014/064251 WO2015036902A1 (en) 2013-09-13 2014-09-04 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Publications (2)

Publication Number Publication Date
MX2015013965A MX2015013965A (es) 2016-02-10
MX367674B true MX367674B (es) 2019-08-30

Family

ID=51688369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013965A MX367674B (es) 2013-09-13 2014-09-04 Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.

Country Status (23)

Country Link
US (1) US9078923B2 (es)
EP (2) EP3043773B1 (es)
JP (2) JP6203967B2 (es)
BR (1) BR112015018252B1 (es)
CY (1) CY1124675T1 (es)
DK (1) DK3043773T3 (es)
ES (1) ES2891729T3 (es)
FR (1) FR21C1057I2 (es)
HR (1) HRP20211515T1 (es)
HU (1) HUE056448T2 (es)
LT (1) LT3043773T (es)
MX (1) MX367674B (es)
MY (1) MY191380A (es)
NL (1) NL301154I2 (es)
NO (1) NO2021045I1 (es)
PH (1) PH12016500433B1 (es)
PL (1) PL3043773T3 (es)
PT (1) PT3043773T (es)
RS (1) RS62383B1 (es)
SI (1) SI3043773T1 (es)
SM (1) SMT202100563T1 (es)
UA (1) UA116793C2 (es)
WO (1) WO2015036902A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370483B2 (en) * 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) * 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
ES2891729T3 (es) * 2013-09-13 2022-01-31 Glenmark Specialty Sa Composición farmacéutica estable de dosis fija que comprende mometasona y olopatadina para la administración nasal
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2016155021A1 (zh) 2015-04-03 2016-10-06 绿仕科技控股有限公司 环境控制系统
ES2849026T3 (es) * 2017-06-28 2021-08-13 Glenmark Specialty Sa Dispositivo dispensador y composición farmacéutica para el tratamiento de la rinitis
TWI790316B (zh) * 2017-12-14 2023-01-21 瑞士商葛蘭馬克專業股份公司 用於向人類經鼻投與之含有水性醫藥組合物的分配裝置
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2020070599A1 (en) * 2018-10-05 2020-04-09 Glenmark Specialty S.A. Nebulization composition of mometasone
CN109602693A (zh) * 2018-11-13 2019-04-12 华润三九（南昌）药业有限公司 糠酸莫米松凝胶及其制备方法
TW202133860A (zh) * 2019-12-06 2021-09-16 日商東興藥品工業股份有限公司 含有類固醇化合物及歐羅派特錠的醫藥組成物
KR20230024928A (ko) * 2020-06-15 2023-02-21 알켐 라보라토리즈 리미티드 알카프타딘과 코르티코스테로이드의 병용
PE20251774A1 (es) 2023-11-21 2025-07-14 Glenmark Specialty Sa Composicion de aerosol nasal
WO2025137749A1 (pt) * 2023-12-27 2025-07-03 Eurofarma Laboratórios S.A. Processo de solubilização de olopatadina e seu uso

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
AU7859800A (en) * 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004043470A1 (en) * 2002-11-12 2004-05-27 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
BRPI0518283A2 (pt) * 2004-11-24 2008-11-11 Alcon Inc mÉtodo para liberar uma aspersço nasal
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US20120121653A1 (en) * 2005-12-02 2012-05-17 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2083798A1 (en) 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
EP2349206A2 (en) * 2008-10-10 2011-08-03 Schering Corporation Corticosteroid compositions and methods of treatments thereof
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (ko) * 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
US20120323178A1 (en) 2011-01-04 2012-12-20 Mitsubishi Tanabe Pharma Corporation Bepotastine compositions
FR2970180B1 (fr) 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
ES2891729T3 (es) * 2013-09-13 2022-01-31 Glenmark Specialty Sa Composición farmacéutica estable de dosis fija que comprende mometasona y olopatadina para la administración nasal

Also Published As

Publication number Publication date
MX2015013965A (es) 2016-02-10
FR21C1057I2 (fr) 2023-02-03
DK3043773T3 (da) 2021-10-04
PH12016500433B1 (en) 2023-03-01
UA116793C2 (uk) 2018-05-10
HRP20211515T1 (hr) 2021-12-24
SMT202100563T1 (it) 2021-11-12
JP2017206560A (ja) 2017-11-24
EP3043773A1 (en) 2016-07-20
NO2021045I1 (no) 2021-10-22
CY1124675T1 (el) 2022-07-22
BR112015018252A2 (pt) 2017-07-18
JP6203967B2 (ja) 2017-09-27
RS62383B1 (sr) 2021-10-29
PH12016500433A1 (en) 2016-05-16
JP6664358B2 (ja) 2020-03-13
NL301154I2 (nl) 2022-07-18
US9078923B2 (en) 2015-07-14
FR21C1057I1 (fr) 2022-01-21
WO2015036902A1 (en) 2015-03-19
PT3043773T (pt) 2021-10-04
ES2891729T3 (es) 2022-01-31
RU2015128497A (ru) 2017-10-18
MY191380A (en) 2022-06-21
HUE056448T2 (hu) 2022-02-28
BR112015018252B1 (pt) 2023-01-10
JP2016534142A (ja) 2016-11-04
LT3043773T (lt) 2021-10-11
RU2015128497A3 (es) 2018-05-11
SI3043773T1 (sl) 2021-12-31
PL3043773T3 (pl) 2021-12-13
US20150079178A1 (en) 2015-03-19
RU2687551C2 (ru) 2019-05-15
EP3718533A1 (en) 2020-10-07
EP3043773B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PH12015500115B1 (en) Glucagon analogues
IN2015DN03219A (es)
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
PH12017502087A1 (en) Tiotropium inhalation solution for nebulization
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
UA113966C2 (xx) Водна рідка фармацевтична композиція, яка містить арбекацин
TN2016000498A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
NZ726131A (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12019501785A1 (en) Intranasal composition comprising betahistine
MX2016006377A (es) Un medicamento inhalable.
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
IN2014MU00184A (es)
IN2014MU00185A (es)
IN2013MU03838A (es)
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLENMARK SPECIALTY S.A.

FG Grant or registration